Please login to the form below

Not currently logged in
Email:
Password:

Cometriq

This page shows the latest Cometriq news and features for those working in and with pharma, biotech and healthcare.

Exelixis bounces back with new prostate cancer data

Exelixis bounces back with new prostate cancer data

Cabozantinib, a c-MET and VEGFR2 inhibitor, is already approved under the brand name Cometriq as a treatment for progressive, metastatic medullary thyroid cancer in the US and Europe.

Latest news

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Ipsen paid $200m upfront for the rights (ex-North America &Japan) to commercialise Cometriq for medullary thyroid cancer and other indications. ... Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics